Latest US Biospecimen Analysis Contracts & Bids

This is a request for continuation of a research contract with the University of Maryland Medical Center. The contract involves collecting and analyzing patient data, biospecimens, and epidemiological data for research on human carcinogenesis. The current contractor has a long history of successful performance, including IRB approvals from two hospitals (University of Maryland Medical Center and the Veterans Affairs Hospital). The notice details the need for a continuation of the contract, emphasizing the importance of maintaining the existing data collection infrastructure and the unique expertise of the current contractor. The contract has been ongoing for almost 30 years, and the data collected is crucial for ongoing research. A sources sought notice was posted on SAM. gov, but no suitable alternative contractors were found. The contracting officer will conduct a cost analysis and cost realism analysis as part of the award decision. The modification action is to add two 12-month option periods to the existing contract, increasing the total estimated contract value.

The contract is for a one-year period of performance. The contractor will deliver sequencing kits to the Department of Veterans Affairs, VISN 16, Central Arkansas Veterans Healthcare System (CAVHS), Pharmacogenomics Analysis Laboratory (PAL). The kits have expiration dates, so shipment must be coordinated with the receiving laboratory to ensure efficient utilization within the year. A communication plan for incremental shipments is required. Shipping notifications must include tracking information, part numbers, quantities, vendor order number, and VA purchase order. A quality control plan for shipping sequencing kits to the VA is required. Final inspection and acceptance of all work will occur at the place of delivery. Changes to the Statement of Work (SOW) require written correspondence from the contracting officer. The government will monitor performance and review deliverables using solicited and unsolicited feedback. The contract is subject to 41 U. S. C. chapter 71, contract disputes. Payment will be made for accepted items delivered to the delivery destinations. The government will make payment in accordance with the prompt payment act and prompt payment regulations. The contractor shall submit an original invoice and three copies or electronic invoice, if authorized, to the address designated in the contract to receive invoices. The contract price includes all applicable federal, state, and local taxes and duties. The government reserves the right to terminate the contract for its sole convenience. The contractor shall comply with all applicable federal, state, and local laws, executive orders, rules, and regulations applicable to its performance under this contract. The contractor agrees to comply with 31 **** relating to limitations on the use of appropriated funds to influence certain federal contracts, 18 U. S. C. 431 relating to officials not to benefit, 40 U. S. C. chapter 37, contract work hours and safety standards, 41 U. S. C. chapter 87, kickbacks, 49 ****, fly American, and 41 U. S. C. chapter 21 relating to procurement integrity. The contractor shall comply with the following FAR clauses, which are incorporated in this contract by reference, to implement provisions of law or executive orders applicable to acquisitions of commercial products and commercial services. The government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the government, price and other factors considered. The government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the government to exercise the options. A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. The offeror shall complete only paragraph b of this provision if the offeror has completed the annual representations and certification electronically in the system for award management (SAM) accessed through www. ***. *. * the offeror has not completed the annual representations and certifications electronically, the offeror shall complete only paragraphs c through v of this provision. The offeror shall enter, in the block with its name and address on the cover page of its offer, the annotation unique entity identifier followed by the unique entity identifier that identifies the offerors name and address. The offeror also shall enter its electronic funds transfer (EFT) indicator, if applicable. The offeror shall submit signed and dated offers to the office specified in this solicitation at or before the exact time specified in this solicitation. Offers

This is a sources sought notice, not a solicitation, to identify qualified small businesses for an indefinite delivery/indefinite quantity (IDIQ) contract supporting clinical research. The notice seeks information on the availability and capability of small businesses to perform clinical trials, including phase 0-4 trials for viral, bacterial, parasitic, fungal pathogens, and toxins, or NIAID priority biodefense pathogens and emerging infectious diseases. Respondents must address the parent contract and all task areas (A, B, and C). Capability statements must not exceed 5 pages, excluding resumes, and must be submitted electronically (in MS Word or Adobe PDF format) by 3:00 PM Eastern Time on 07/02/2025 to ***@***. *. * subject line must include the reference number 75n93025r00019. The anticipated period of performance is 10 years with an ordering period of 7 years, starting on or about July 2026.

This is a sources sought notice, not a solicitation, to identify qualified small businesses for an indefinite delivery/indefinite quantity (IDIQ) contract supporting clinical research. The notice seeks information on the availability and capability of small businesses to perform clinical trials, including phase 0-4 trials for viral, bacterial, parasitic, fungal pathogens, and toxins, or NIAID priority biodefense pathogens and emerging infectious diseases. Respondents must address the parent contract and all task areas (A, B, and C). Capability statements must not exceed 5 pages, excluding resumes, and must be submitted electronically (in MS Word or Adobe PDF format) by 3:00 PM Eastern Time on 07/02/2025 to ***@***. *. * subject line must include the reference number 75n93025r00019. The anticipated period of performance is 10 years with an ordering period of 7 years, starting on or about July 2026.